Immunogenicity risk assessment of synthetic peptide drugs and their impurities

Drug Discov Today. 2023 Jul 17:103714. doi: 10.1016/j.drudis.2023.103714. Online ahead of print.ABSTRACTPeptide drugs play an important part in medicine owing to their many therapeutic applications. Of the 80 peptide drugs approved for use in humans, at least five are now off-patent and are consequently being developed as generic alternatives to the originator products. To accelerate access to generic products, the FDA has proposed new regulatory pathways that do not require direct comparisons of generics to originators in clinical trials. The 'Abbreviated New Drug Application' (ANDA) pathway recommends that sponsors provide information on any new impurities in the generic drug, compared with the originator product, because the impurities can have potential to elicit unwanted immune responses owing to the introduction of T-cell epitopes. This review describes how peptide drug impurities can elicit unexpected immunogenicity and describes a framework for performing immunogenicity risk assessment of all types of bioactive peptide products. Although this report primarily focuses on generic peptides and their impurities, the approach might also be of interest for developers of novel peptide drugs who are preparing their products for an initial regulatory review.PMID:37467878 | DOI:10.1016/j.drudis.2023.103714
Source: Drug Discovery Today - Category: Drugs & Pharmacology Authors: Source Type: research